| Autor: |
Ruth A. Ross, Roger G. Pertwee, Raphael Mechoulam, Ken Mackie, George Kunos, Allyn C. Howlett, Miles Herkenham, Peter Greasley, Christian C. Felder, Maurice R. Elphick, Vincenzo Di Marzo, William A. Devane, Ben F. Cravatt, Pierre Casellas, Guy Cabral, Heather Bradshaw, Tom I. Bonner, Francis Barth, Stephen P.H. Alexander, Mary Abood |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
IUPHAR/BPS Guide to Pharmacology CITE. 2023 |
| ISSN: |
2633-1020 |
| Popis: |
Cannabinoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Cannabinoid Receptors [119]) are activated by endogenous ligands that include N-arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [5].There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB1 and CB2 receptors [111]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are nabilone (Cesamet®), a synthetic CB1/CB2 receptor agonist, and synthetic Δ9-tetrahydrocannabinol (Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly Δ9-tetrahydrocannabinol and cannabidiol, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
